Unraveling Chemotherapy Resistance: Linking Tumor Metabolism, Cachexia, and Organoid InnovationRedefining Prognosis and Personalized Care in Cancer Through Advanced Body Composition and Metabolic Research

Our research laboratory is leading the way in transforming how cancer patient outcomes are predicted and managed. By integrating advanced body composition analysis, systemic inflammation markers, and innovative metabolic studies, we are uncovering new predictors of survival and pioneering novel interventions for cancer cachexia.

Our Breakthroughs and Innovations: 

• Enhanced Survival Prediction

We have demonstrated that combining multiple body composition parameters with systemic inflammatory markers provides a more accurate prediction of patient survival than traditional tumor staging. This approach enables clinicians to better identify high-risk patients and personalize their care.

• Ectopic Fat as a Key Indicator

Our studies reveal that fat accumulation in the liver and muscle—known as ectopic fat deposition—serves as an independent predictor of both survival and the risk of infectious complications following surgery.

• Microbiome-Driven Nutritional Support

Our unique analyses of the gut microbiome in cancer patients, correlated with cachexia status, have provided the foundation for developing a prebiotic intervention. This approach could offer a new avenue for developing novel ways of nutritional support in cancer care.

• Metabolic Insights with Stable Isotope Tracing

Leveraging our expertise in stable isotope tracing, we have mapped protein metabolism across different organs in cachectic cancer patients. Notably, we found that tumor protein synthesis is significantly lower than that of surrounding healthy pancreatic tissue, muscle, and adipose tissue, offering new insights into the metabolic alterations of cancer cachexia.